Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs

Lucy Platt, Jennifer Reed, Silvia Minozzi, Peter Vickerman, Holly Hagan, Clare French, Ashly Jordan, Louisa Degenhardt, Vivian Hope, Sharon Hutchinson, Lisa Maher, Norah Palmateer, Avril Taylor, Matthew Hickman

Research output: Contribution to journalArticle

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the impact of needle/syringe programmes with and without opiate substitution therapy (OST) on the incidence of HCV infection among people who inject drugs (PWID). To assess the effect of OST alone on the incidence of HCV infection among PWID. Research questions: How effective are needle/syringe programmes (NSP) with and without the use of OST for reducing HCV incidence among PWID? How effective is OST alone for reducing HCV incidence among PWID? How does the effect of NSP and OST vary according to duration of treatment (i.e. for NSPs weekly attendance versus monthly)? How does the effect of NSP vary according to the type of service (fixed site versus mobile; high coverage versus low coverage)? How does the effect of OST vary according to the dosage of OST, type of substitution used and adherence to treatment?

Original languageEnglish (US)
Article numberCD012021
JournalCochrane database of systematic reviews (Online)
Volume2016
Issue number1
DOIs
StatePublished - Jan 12 2016

Fingerprint

Opiate Alkaloids
Syringes
Needles
Pharmaceutical Preparations
Incidence
Therapeutics
Infection

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. / Platt, Lucy; Reed, Jennifer; Minozzi, Silvia; Vickerman, Peter; Hagan, Holly; French, Clare; Jordan, Ashly; Degenhardt, Louisa; Hope, Vivian; Hutchinson, Sharon; Maher, Lisa; Palmateer, Norah; Taylor, Avril; Hickman, Matthew.

In: Cochrane database of systematic reviews (Online), Vol. 2016, No. 1, CD012021, 12.01.2016.

Research output: Contribution to journalArticle

Platt, L, Reed, J, Minozzi, S, Vickerman, P, Hagan, H, French, C, Jordan, A, Degenhardt, L, Hope, V, Hutchinson, S, Maher, L, Palmateer, N, Taylor, A & Hickman, M 2016, 'Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs', Cochrane database of systematic reviews (Online), vol. 2016, no. 1, CD012021. https://doi.org/10.1002/14651858.CD012021
Platt, Lucy ; Reed, Jennifer ; Minozzi, Silvia ; Vickerman, Peter ; Hagan, Holly ; French, Clare ; Jordan, Ashly ; Degenhardt, Louisa ; Hope, Vivian ; Hutchinson, Sharon ; Maher, Lisa ; Palmateer, Norah ; Taylor, Avril ; Hickman, Matthew. / Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. In: Cochrane database of systematic reviews (Online). 2016 ; Vol. 2016, No. 1.
@article{ba67005a9afe4aef9cfbfabfeb0b57e0,
title = "Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs",
abstract = "This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the impact of needle/syringe programmes with and without opiate substitution therapy (OST) on the incidence of HCV infection among people who inject drugs (PWID). To assess the effect of OST alone on the incidence of HCV infection among PWID. Research questions: How effective are needle/syringe programmes (NSP) with and without the use of OST for reducing HCV incidence among PWID? How effective is OST alone for reducing HCV incidence among PWID? How does the effect of NSP and OST vary according to duration of treatment (i.e. for NSPs weekly attendance versus monthly)? How does the effect of NSP vary according to the type of service (fixed site versus mobile; high coverage versus low coverage)? How does the effect of OST vary according to the dosage of OST, type of substitution used and adherence to treatment?",
author = "Lucy Platt and Jennifer Reed and Silvia Minozzi and Peter Vickerman and Holly Hagan and Clare French and Ashly Jordan and Louisa Degenhardt and Vivian Hope and Sharon Hutchinson and Lisa Maher and Norah Palmateer and Avril Taylor and Matthew Hickman",
year = "2016",
month = "1",
day = "12",
doi = "10.1002/14651858.CD012021",
language = "English (US)",
volume = "2016",
journal = "Cochrane Database of Systematic Reviews",
issn = "1361-6137",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs

AU - Platt, Lucy

AU - Reed, Jennifer

AU - Minozzi, Silvia

AU - Vickerman, Peter

AU - Hagan, Holly

AU - French, Clare

AU - Jordan, Ashly

AU - Degenhardt, Louisa

AU - Hope, Vivian

AU - Hutchinson, Sharon

AU - Maher, Lisa

AU - Palmateer, Norah

AU - Taylor, Avril

AU - Hickman, Matthew

PY - 2016/1/12

Y1 - 2016/1/12

N2 - This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the impact of needle/syringe programmes with and without opiate substitution therapy (OST) on the incidence of HCV infection among people who inject drugs (PWID). To assess the effect of OST alone on the incidence of HCV infection among PWID. Research questions: How effective are needle/syringe programmes (NSP) with and without the use of OST for reducing HCV incidence among PWID? How effective is OST alone for reducing HCV incidence among PWID? How does the effect of NSP and OST vary according to duration of treatment (i.e. for NSPs weekly attendance versus monthly)? How does the effect of NSP vary according to the type of service (fixed site versus mobile; high coverage versus low coverage)? How does the effect of OST vary according to the dosage of OST, type of substitution used and adherence to treatment?

AB - This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the impact of needle/syringe programmes with and without opiate substitution therapy (OST) on the incidence of HCV infection among people who inject drugs (PWID). To assess the effect of OST alone on the incidence of HCV infection among PWID. Research questions: How effective are needle/syringe programmes (NSP) with and without the use of OST for reducing HCV incidence among PWID? How effective is OST alone for reducing HCV incidence among PWID? How does the effect of NSP and OST vary according to duration of treatment (i.e. for NSPs weekly attendance versus monthly)? How does the effect of NSP vary according to the type of service (fixed site versus mobile; high coverage versus low coverage)? How does the effect of OST vary according to the dosage of OST, type of substitution used and adherence to treatment?

UR - http://www.scopus.com/inward/record.url?scp=84969523077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969523077&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD012021

DO - 10.1002/14651858.CD012021

M3 - Article

VL - 2016

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1361-6137

IS - 1

M1 - CD012021

ER -